@article{620a330bc5e94ab4ac4194e5113e2e98,
title = "Changes in hepatitis B vaccine perception in response to the COVID-19 pandemic: Development of the Shift in vaccine confidence (SVC) survey tool",
abstract = "The COVID-19 pandemic has disrupted access to, adherence to, and perceptions of routine vaccinations. We developed the Shift in Vaccine Confidence (SVC) survey tool to assess the impact of the pandemic on routine vaccinations, with a focus on the HBV vaccine, in Kinshasa, Democratic Republic of Congo (DRC). This study describes the content validation steps we conducted to ensure the survey tool is meaningful to measure changes in vaccine confidence to regular immunization (HBV vaccine) due to the pandemic. Three rounds of stakeholder feedback from a DRC-based study team, content and measurement experts, and study participants allowed us to produce a measure with improved readability and clarity.",
keywords = "COVID-19 vaccine, Survey tool, Vaccine hesitancy, hepatitis B virus vaccine",
author = "Alix Boisson and Morgan, {Camille E.} and Angela Stover and Patrick Ngimbi and Nana Mbonze and Sarah Ntambua and Jolie Matondo and Parr, {Jonathan B.} and Marcel Yotebieng and Kashamuka Mwandagalirwa and Linda James and Samuel Mampunza and Peyton Thompson",
note = "Funding Information: This study builds upon the parent HOVER-HBV study, funded by Gilead Sciences, Inc (ISR-US-18–10486). This study is funded, in part, by a Postdoctoral Fellowship in Tropical Infectious Diseases from the American Society for Tropical Medicine and Hygiene (ASTMH)/Burroughs-Wellcome Fund granted to PT. AS received funding in part from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR002489. Outside of this work, PT received funding from the NIH (K08AI148607). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: CEM reports funding from NIH grant (NIGMS T32GM008719) and a fellowship from the University of North Carolina Graduate School, outside of this work. AB reports a grant by the Drusilla L. Scott Summer Research Fellowship. JBP reports grants from the US National Institutes of Health (NIH), outside the submitted work. PT is funded by grants from the NIH (K08AI148607) and Novavax (2019nCoV-301), outside of this work. AS receives unrelated research funding from PCORI, NIH, AHRQ, Bladder Cancer Advocacy Network, American Society of Clinical Oncology, Sivan Innovation, UroGen Pharma ltd, and Pfizer Global, all outside of this work. PT and JBP report support from American Society of Tropical Medicine and Hygiene–Burroughs Wellcome Fund awards, outside the submitted work; they also report research funding from Gilead Sciences, Inc, for the parent study. JBP, PT, and MY report non-financial support from Abbott Laboratories. JBP also receives research support from the World Health Organization and honorarium from Virology Education, both outside the scope of the submitted work. AS has received unrelated consulting fees or speaking honoraria in the last 24 months from: Navigating Cancer, Association of Community Cancer Centers, Pfizer, Genentech, Purchaser Business Group on Health, and Henry Ford Cancer Center. All other authors declare no competing interests. Funding Information: This study builds upon the parent HOVER-HBV study, funded by Gilead Sciences, Inc (ISR-US-18–10486). This study is funded, in part, by a Postdoctoral Fellowship in Tropical Infectious Diseases from the American Society for Tropical Medicine and Hygiene (ASTMH)/Burroughs-Wellcome Fund granted to PT. We thank all of the women who participated in this study. We also thank the staff at the Binza and Kingasani maternity clinics, and provincial and national health authorities. We are especially grateful for the contributions of Bienvenu Kawende and Noro Lantoniaina Rosa Ravelomanana to the planning of the parent HOVER study. We grieve the loss of Prof Steven Meshnick, who had a major role in the parent study and whose vision and mentorship were critical to its success. Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2023",
month = jan,
day = "16",
doi = "10.1016/j.vaccine.2022.12.028",
language = "English (US)",
volume = "41",
pages = "623--629",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",
}
